反応式
CC(C)(C)OC(=O)N1CCNCC1.COC(=O)c1ccc(I)cc1O>COCCOC.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C([O-])[O-].[Cs+].[Cs+].[Pd].[Pd].c1ccc(P(c2ccccc2)c2ccc3ccccc3c2-c2c(P(c3ccccc3)c3ccccc3)ccc3ccccc23)cc1>COC(=O)c1ccc(N2CCN(C(=O)OC(C)(C)C)CC2)cc1O参加物
7
反応条件
- 温度
- 90 °C
実験手順
tert-butyl piperazine-1-carboxylate (0.670 g, 3.60 mmol) and methyl 2-hydroxy-4-iodobenzoate (1 g, 3.60 mmol), BINAP (0.224 g, 0.36 mmol), cesium carbonate (2.461 g, 7.55 mmol) were put inDME (18 mL), tris(dibenzylideneacetone)dipalladium(0) (0.165 g, 0.18 mmol) was added last. Reaction wsa purged by nitrogen, and heated at90 °C overnight. No desired product was found.
出典と根拠
- ORDレコード
- ord-50654e3db36e4cb59399fcb1f475b246
- 出典データセット
- 750 AstraZeneca ELN dataset
- 元リンク
- 出典を表示
関連ノート
読み込み中…